- Email:
Neurotoxicity Screening Service
Introduction
Neurotoxicity screening plays a critical role in safety pharmacology. Creative Biolabs' professional neurotoxicity screening service surmounts the limitations of conventional models by evaluating neuronal function and glial cell health to deliver robust safety data, supporting CNS drug optimization, regulatory filings, and environmental safety assessments.
Discover How We Can Help - Request a Consultation →
Neurotoxicity Screening Service
Neurotoxicity testing assesses the potential damage of compounds, drugs, or environmental factors to neural cells and networks. It is essential to identify neurotoxic risks early, ensure the safety of CNS drugs and environmental substances, and avoid clinical trial attrition and potential harm to human nervous systems.
Neurotoxicity Detection Methods
- Neuronal Viability Assay: Detect neuronal damage and cell viability using standardized cytotoxicity detection methods to evaluate the impact of test substances on neuronal survival.
- LDH Cytotoxicity Assay: Detects lactate dehydrogenase (LDH) release to evaluate neuronal damage and cell viability caused by neurotoxic substances, providing quantitative data on cytotoxicity levels.
- Neuronal Morphology Evaluation: Assess changes in neurite outgrowth, network formation, and cell distribution through automated imaging, reflecting structural damage induced by neurotoxins.
- Electrophysiological Testing: Measure neuronal excitability, synaptic transmission, and network firing patterns to detect functional impairments caused by neurotoxic compounds.
Service Applications
| Drug Safety Evaluation | Screen candidate drugs (e.g., neurotherapeutics, CNS drugs) for potential neurotoxicity, supporting preclinical safety assessment and regulatory compliance. |
| Environmental Toxicology | Evaluate neurotoxic effects of environmental pollutants, industrial chemicals, and food additives on human neural systems. |
| Neurodegenerative Disease Research | Identify compounds that induce neuronal damage similar to neurodegenerative disorders (e.g., Alzheimer's, Parkinson's), aiding in pathogenesis studies. |
| High-Throughput Drug Screening | Rapidly screen large compound libraries to filter out neurotoxic candidates, accelerating neuropharmaceutical R&D progress. |
Workflow
Our workflow is designed to provide a seamless transition from compound submission to detailed mechanistic analysis, ensuring every project is grounded in robust scientific rigor.
What We Can Offer
At Creative Biolabs, we go beyond standard assays by providing a high-capacity, GMP-aligned screening environment. Our Neurotoxicity Screening Service is built to handle the most complex biological questions with a focus on precision and scalability.
All-scale 3D Modeling
One-stop service for human iPSC-derived 2D and 3D organoid models, spanning laboratory-scale validation to high-throughput screening.
Advanced Functional Profiling
Utilization of HD-MEA technology with thousands of sensors to capture high-resolution network dynamics and synchronous bursting.
Integrated Metabolic Bioactivation
Seamless coupling of neural assays with S9 fractions or human liver microsomes (HLM) to bridge the "metabolic gap."
High-Standard Quality Control
Implementation of Quality-by-Design (QbD) and Hazard Analysis Critical Control Point (HACCP) principles to ensure data reproducibility.
Strict Validation Procedures
Aseptic verification and standardized protocols throughout the cell maturation and compound exposure process.
Customized Service Solutions
We offer fully bespoke assay designs, including specific neural lineage differentiation (e.g., sensory, motor, or dopaminergic) tailored to your project's unique target profile.
Regulatory Alignment
Data generation designed to support submissions under the FDA Modernization Act 2.0 and OECD guidelines for animal-free toxicological testing.
Experience the Creative Biolabs Advantage - Get a Quote Today →
Case Study
To address the poor human relevance of traditional models, researchers constructed a human iPSC-derived 3D Brain Sphere model containing neurons and glial cells. Combined with HD-MEA, it was used to conduct 13-day exposure neurotoxicity tests on 10 compounds, monitoring electrophysiological indicators such as firing rate and spike amplitude. Results confirmed the model can accurately identify compound-induced concentration-dependent neurotoxicity and effectively distinguish toxic from non-toxic substances, providing a highly physiologically relevant solution for in vitro neurotoxicity screening.
Fig.1 Utilizing a 3D human iPSC-derived brain microphysiological system model and high-density microelectrode arrays for detection, this is used for screening the neurotoxicity of compounds in an in vitro environment.1
Customer Reviews
FAQ
Q: How do your 3D Brain Spheres differ from standard 2D neural cultures?
A: 2D cultures lack the tissue architecture and glial-neuronal interactions of the human brain. Our 3D Brain Spheres include neurons, astrocytes, and oligodendrocytes, allowing for the study of myelination and complex network bursting that better predicts human response.
Q: What is the significance of the "Metabolic Gap" in your screening?
A: Many compounds are only toxic after liver metabolism. By coupling our neural assays with S9 fractions or HLM, we identify these "pro-toxicants" that would otherwise result in false negatives in standard brain-only assays.
Q: Is your HD-MEA platform compatible with high-throughput needs?
A: Yes. Our multi-well HD-MEA system allows for the screening of multiple compounds or concentrations simultaneously, providing high-resolution functional data without compromising throughput.
Q: Can you model developmental neurotoxicity (DNT)?
A: Certainly. We use long-term exposure protocols (14+ days) during critical windows of iPSC differentiation to monitor effects on synaptogenesis and circuit formation.
Q: How do you handle compounds with low solubility or high protein binding?
A: Our team optimizes the assay media and exposure conditions (e.g., adjusting protein content or using specialized solvents) to ensure accurate dose-response modeling for challenging molecules.
Creative Biolabs offers a world-class suite of neurotoxicity screening services tailored for the pharmaceutical and environmental sectors. By combining 3D Brain Spheres, metabolic simulation, and high-resolution electrophysiology, we help you navigate the complexities of CNS drug development and safety assessment with confidence.
Contact Our Team for More Information and to Discuss Your Project →
Reference
- Carstens, Kelly E., et al. "Application of a high-density microelectrode array assay using a 3D human iPSC-derived brain microphysiological system model for in vitro neurotoxicity screening of environmental compounds." Archives of toxicology 99.7 (2025): 2917-2935. Distributed under Open Access license CC BY 4.0, the figure was cropped. https://doi.org/10.1007/s00204-025-04043-x.
For Research Use Only. Not For Clinical Use.